Điều trị tăng huyết áp: Vai trò hiện nay của thuốc chẹn beta giao cảm?
Tóm tắt
Điều trị tăng huyết áp: Vai trò hiện nay của thuốc chẹn beta giao cảm?Tài liệu tham khảo
1. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507- 20. doi: 10.1001/jama.2013.284427.
2. Messerli FH, Grossman E, Goldbourt U. Are ß-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279:1903-1907.
3. Dahlöf B, Devereux RB, Kjeldsen SE, et al for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
4. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364:1684-1689.
5. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
6. Neutel JM, Schnaper H, Cheung DG, Graettinger WF, Weber MA. Antihypertensive effects of ß-blockers administered once daily: 24-hour measurements. Am Heart J 1990; 120:166-171.
7. Lindholm LH, Carlberg B, Samuelsson O. Should ß-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
8. Wiysonge CS, Bradley H, Mayosi BM, et al. ß-blockers for hyper-tension. Cochrane Database Syst Rev 2007; CD002003.
9. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96:308-315.
10. The IPPPSH Collaborative Group. Cardiovascular risk and risk fac-tors in a randomized trial of treatment based on the ß-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3:379-392.
11. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Preven-tion of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Car-diac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
12. Khan N, McAlister FA. Re-examining the efficacy of ß-blockers for the treatment of hypertension: a meta- analysis. CMAJ 2006; 174:1737-1742.
13. Bangalore S, Sawhney S, Messerli FH. Relation of ß-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008; 52:1482-1489.
14. Kveiborg B, Christiansen B, Major-Petersen A, Torp-Pedersen C. Metabolic effects of ß-adrenoceptor antagonists with special emphasis on carvedilol. Am J Cardiovasc Drugs 2006; 6:209-217.
15. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with ß-blockers to de-termine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100:1254-1262.
16. Pedersen ME, Cockcroft JR. The latest generation of ß-blockers: new pharmacologic properties. Curr Hypertens Rep 2006; 8:279-286.
17. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Park-homenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker S, Thompson SG, Poole-Wilson PA, and the SENIORS Investigators: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly pa-tients with heart failure (SENIORS). Eur Heart J 2005;26:215-225.
18. Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JI: A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997;11:139 -144.
19. Fallois JV, Faulhaber H-D: Nebivolol, a ß-blocker of the third generation: the current treatment of arterial hypertension: results of a multicenter observational study. Praxis 2001;90:435- 441.
20. Van Nueten L, Taylor FR, Robertson JIS: Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 1998;12:135-140.
21. Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G: Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl 2003;2:35- 40.
22. Uhlír˘ O, Fejfus˘ a M, Havránek K, Lefflerová K, Vojác˘ ek J, Widim-sky´ J, Winterová J, Zeman K: Nebivolol versus metoprolol in the treatment of hypertension. Drug Invest 1991;3(Suppl 1):107-110.
23. Luc M Van Bortel, Francesco Fici, Flavio Mascagni: Efficacy and Tolerability of Nebivolol Compared with Other Antihypertensive Drugs. Am J Cardiovasc Drugs 2008; 8 (1): 35-44.
24. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hyperten-sive patients. J Hypertens 2001; 19:1429-1435.
25. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26:351-356.
